Indication |
Used in short-term (a few weeks) treatment of exogenous obesity in
conjunction with a regimen of weight reduction based on caloric
restriction, exercise, and behavior modification in patients with a body
mass index of 30 kg of body weight per height in meters squared (kg/m2) or in patients with a body mass index of 27 kg/m2 in the presence of risk factors such as hypertension, diabetes, or hyperlipidemia. |
Pharmacodynamics |
Mazindol is a sympathomimetic amine, which is similar to an
amphetamine. Mazindol stimulates the central nervous system (nerves and
brain), which increases your heart rate and blood pressure and decreases
your appetite. Sympathomimetic appetite suppressants are used in the
short-term treatment of obesity. Their appetite-reducing effect tends to
decrease after a few weeks. Because of this, these medicines are useful
only during the first few weeks of a weight-loss program. |
Mechanism of action |
Although the mechanism of action of the sympathomimetics in the
treatment of obesity is not fully known, these medications have
pharmacological effects similar to those of amphetamines. Unlike other
sympathomimetic appetite suppressants such as phentermine, mazindol is
thought to inhibit the reuptake of norepinephrine rather than to cause
its release. |
Absorption |
Not Available |
Volume of distribution |
Not Available |
Protein binding |
Not Available |
Metabolism |
Hepatic. |
Route of elimination |
Not Available |
Half life |
10-13 hours |
Clearance |
Not Available |
Toxicity |
Symptoms of a mazindol overdose include restlessness, tremor,
rapid breathing, confusion, hallucinations, panic, aggressiveness,
nausea, vomiting, diarrhea, an irregular heartbeat, and seizures. |